The Immunotherapy Series, Part Three: Policy and the FDA

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?Special guests:Meghan GutierrezChief Executive OfficerLymphoma Research FoundationLeo David Wang, M.D., Ph.D.Assistant Professor, Department of Immuno-OncologyAssistant Professor, Department of PediatricsCity Of HopeThis series is brought to you ad-free by Adaptive BiotechnologiesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.